CDNA stock forecast, quote, news & analysis
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers... Show more
Why CareDx (CDNA) Stock Is Up +29.6% in the Last 30 Days
Key Takeaways
- CareDx (CDNA) shares have climbed roughly 29.6% over the trailing 30 days, from about $53.83 to approximately $69.74.
- The move was propelled by a raised analyst price target from BTIG and renewed confidence following the positive resolution of a Medicare transplant coverage determination.
- Strong transplant testing demand, an expanded oncology pipeline, and raised full-year guidance have underpinned sustained investor enthusiasm.
- The stock has also risen sharply over the trailing three months, reflecting a broader re-rating of the precision diagnostics business.
CareDx (CDNA) Company Overview and Market Position
CareDx, Inc., branded as "The Transplant Company," is a precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy. Its portfolio includes non-invasive molecular monitoring tests such as AlloMap Heart, AlloSure Kidney, AlloSure Heart, and AlloSure Lung, alongside integrated digital health and patient-support solutions that span the care journey before and after transplantation.
The company is a leading provider of genomics-based information for transplant patients, with workflows embedded across a large share of U.S. transplant centers. Investors follow CDNA closely because its testing business generates recurring, reimbursed revenue tied to longitudinal patient monitoring, while newer initiatives — including the AlloHeme cell therapy test and the acquisition of oncology diagnostics provider Naveris — extend its model into adjacent high-value markets.
CareDx (CDNA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CareDx shares have advanced from a closing level of roughly $53.83 to approximately $69.74, a gain of about 29.6%. The advance accelerated in late September, when the stock jumped roughly 13% in a single session following a bullish analyst action, before consolidating and pushing to new recent highs into mid-October.
The quarterly picture is even stronger. Over the trailing three months, shares have risen from roughly $38 in mid-July to current levels, a gain of about 82%. This multi-month surge reflects a sustained re-rating driven by better-than-expected earnings, raised guidance, and progress on the company's strategic transformation, rather than a single isolated catalyst.
What Drove CDNA Stock Price in the Last 30 Days
Several verified developments shaped the recent 30-day move. In late September, BTIG raised its price target on CareDx to $74 from $60 while reiterating a Buy rating, citing management's confidence after the positive resolution of a Medicare transplant local coverage determination (LCD), strong growth in the core transplant testing business, and the oncology pipeline including the Naveris acquisition. The announcement drove a double-digit single-day gain.
The favorable LCD outcome removed a meaningful reimbursement overhang that had weighed on sentiment earlier in the year. With clearer coverage visibility for surveillance testing across kidney, heart, and lung transplants, investors gained confidence in the durability of the company's core revenue stream. Additionally, anticipation has built ahead of CareDx's third-quarter 2026 results, which the company scheduled to report in late October.
Broader market rotation toward precision diagnostics and names with accelerating, reimbursed revenue growth has also contributed to positive sentiment, though company-specific fundamentals remain the dominant driver of the move.
What Drove CDNA Stock Performance Over the Last Quarter
The stock's larger quarterly advance reflects a series of fundamental milestones. In its second-quarter 2026 report, CareDx posted revenue of $132 million, up 52% year over year, while adjusted net income more than tripled to $20 million, or $0.37 per share. The company simultaneously raised its full-year 2026 revenue guidance to $490 million to $500 million and lifted its adjusted EBITDA outlook to $66 million to $78 million.
Earlier in the quarter, the Centers for Medicare & Medicaid Services affirmed coverage for CareDx's transplant surveillance testing, strengthening the reimbursement foundation. Strategically, the company completed its acquisition of Naveris, an oncology diagnostics provider focused on tumor-naive minimal residual disease (MRD) testing for viral-mediated cancers, and announced the divestiture of its Lab Products business for $170 million in upfront cash. These portfolio actions streamline the business around higher-growth testing and digital solutions while funding expansion into specialty oncology.
Trending AI Robots
For traders and investors seeking a systematic edge, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are surfaced in this section. These bots vary in strategy, timeframe, and performance metrics, allowing users to explore approaches ranging from short-term swing trading to longer-horizon models. The selection is designed to help market participants quickly identify strategies that are currently resonating with market conditions. Reviewing the featured robots can provide a useful, data-driven complement to fundamental research.
CDNA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important near-term catalyst is CareDx's third-quarter 2026 earnings report, scheduled for late October, along with any updates to full-year guidance. Investors will also monitor the integration of Naveris and the trajectory of its MRD testing volumes, as well as progress on pipeline programs such as AlloHeme and AlloSure Liver. Reimbursement policy remains a key sensitivity, given the sector's dependence on Medicare coverage determinations. Competitive dynamics in transplant and oncology diagnostics — including against players such as Natera (NTRA) — and broader healthcare spending trends are additional factors to watch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CDNA in -13.72% downward trend, sliding for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CDNA declined for three days, in 230 of 272 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for CDNA moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 25 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 54 cases where CDNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 70%.
CDNA broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CDNA as a result. In 79 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for CDNA just turned positive on October 28, 2026. Looking at past instances where CDNA's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.
Following a +10.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDNA advanced for three days, in 244 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 203 of 224 cases where CDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. CDNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.549) is normal, around the industry mean (67.298). P/E Ratio (36.370) is within average values for comparable stocks, (4.239). CDNA's Projected Growth (PEG Ratio) (48.410) is very high in comparison to the industry average of (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.146) is also within normal values, averaging (9.775).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a molecular diagnostics company which develops, markets and delivers diagnostic surveillance solutions for organ transplant recipients
Industry MedicalSpecialties